87例上皮性卵巢癌铂耐药患者的预后及影响因素分析

Analysis of prognosis and influencing factors of 87 cases of epithelial ovarian cancer patients with platinum resistance

目的分析87例上皮性卵巢癌(EOC)铂耐药患者的预后及影响因素。方法选取87例EOC铂耐药患者作为研究对象,收集患者的临床资料并进行随访。比较不同临床特征患者的生存时间;使用Cox回归分析法分析影响EOC铂耐药患者生存时间的因素。结果87例EOC铂耐药患者的中位生存时间为20个月。行二次肿瘤细胞减灭术、二次化疗周期≥6个、行放疗、无腹水的EOC铂耐药患者生存时间明显长于未行二次肿瘤细胞减灭术、二次化疗周期<6个、未行放疗、有腹水的患者(P<0.05)。Cox回归分析结果显示,二次肿瘤细胞减灭术、二次化疗周期、放疗、腹水均对EOC铂耐药患者生存时间有显著影响(P<0.05)。结论EOC铂耐药患者的中位生存时间为20个月,临床中应积极对EOC铂耐药患者进行健康教育,尤其是对于合并腹水的患者,在患者可耐受的情况下,根据医师建议开展二次肿瘤细胞减灭术、系统的二次化疗及放疗等治疗措施,以有效延长患者的生存时间,改善预后。

Objective To analyze the prognosis and influencing factors of 87 cases of epithelial ovarian cancer(EOC)patients with platinum resistance.Methods A total of 87 EOC patients with platinum resistance were selected as the research objects,and clinical data of the patients were collected and followed up.The survival time of patients with different clinical characteristics were compared;Cox regression analysis method was used to analyze the factors affecting the survival time of EOC platinum resistant patients.Results The median survival time of 87 EOC platinum resistant patients was 20 months.The survival time of EOC platinum resistant patients who underwent secondary cytoreductive surgery,secondary chemotherapy cycle≥6,radiotherapy and no ascites were significantly longer than those of who without secondary cytoreductive surgery,secondary chemotherapy cycle<6,without radiotherapy and had ascites(P<0.05).Cox regression analysis result showed that the secondary cytoreductive surgery,secondary chemotherapy cycle,radiotherapy and ascites had a significant impact on the survival time of EOC platinum resistant patients(P<0.05).Conclusion The median survival time of EOC platinum resistant patients is 20 months,and health education for EOC platinum resistant patients should be actively carried out in clinical practice.Especially for patients with ascites,if the patient can tolerate it,follow the physician's recommendation to carry out secondary cytoreductive surgery,systemic secondary chemotherapy and radiotherapy and other treatment measures to effectively prolong the survival time of the patient and improve the prognosis.